Technosphere Insulin (Afrezza): A New, Inhaled Prandial Insulin

Annals of Pharmacotherapy

Volumn 49, Issue 1, 2015, Pages 99-106

  Nuffer, Wesley ^a   Trujillo, Jennifer M ^a   Ellis, Samuel L ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

diabetes; inhaled insulin; insulin; Technosphere

Indexed keywords

INSULIN LISPRO; RECOMBINANT HUMAN INSULIN; ANTIDIABETIC AGENT; INSULIN;

AREA UNDER THE CURVE; ASTHMA; BOLUS INJECTION; BRONCHOSPASM; CHRONIC LUNG DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COUGHING; DRUG BIOAVAILABILITY; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; LUNG CANCER; LUNG FUNCTION; LUNG FUNCTION TEST; MAXIMUM PLASMA CONCENTRATION; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT ATTITUDE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REVIEW; SAMPLE SIZE; SMOKING; SYSTEMATIC REVIEW; TIME TO MAXIMUM PLASMA CONCENTRATION; UPPER RESPIRATORY TRACT INFECTION; CHEMICALLY INDUCED; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; INHALATIONAL DRUG ADMINISTRATION;

ADMINISTRATION, INHALATION; COUGH; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FORCED EXPIRATORY VOLUME; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN;

EID: 84919622380     PISSN: 10600280     EISSN: 15426270     Source Type: Journal    
DOI: 10.1177/1060028014554648     Document Type: Review

References (27)

1. National Diabetes Statistics Report, 2014. Atlanta, GA: Centers for Disease Control and Prevention, 2014. http://www.cdc.gov/diabetes/pubs/statsreport14/national-diabetes-report-web.pdf. Accessed August 25, 2014.
2. Hamaty M.Insulin treatment for type 2 diabetes: when to start, which to use.Cleve Clin J Med. 2011;78:332-342
3. Rolla AR.Progression of type 2 diabetes and insulin initiation.J Natl Med Assoc. 2011;103:241-246
4. Peyrot M,Rubin RR,Lauritzen T, et al.Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study.Diabetes Care. 2005;28:2673-2679
5. Glasgow RE,McCaul KD,Schafer LC.Barriers to regimen adherence among persons with insulin-dependent diabetes.J Behav Med. 1986;9:65-77
6. Hayes RP,Fitzgerald JT,Jacober SJ.Primary care physician beliefs about insulin initiation in patients with type 2 diabetes.Int J Clin Pract. 2008;62:860-868
7. Mannkind Corporation Briefing Document: Endocrinology and Metabolic Drug Advisory Committee. AFREZZA: (insulin human [rDNA origin]) inhalation powder. http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/endocrinologicandmetabolicdrugsadvisorycommittee/ucm390865.pdf. Accessed August 25, 2014.
8. Rave K,Potocka E,Heinemann L, et al.Pharmacokinetics and linear exposure of AFRESA compared with the subcutaneous injection of regular human insulin.Diabetes Obes Metab. 2009;11:715-720
9. Pfutzner A,Forst T.Pulmonary insulin delivery by means of the Technosphere drug carrier mechanism.Expert Opin Drug Deliv. 2005;2:1097-1106
10. Potocka E,Baughman RA,Derendorf H.Population pharmacokinetic model of human insulin following different routes of administration.J Clin Pharmacol. 2011;51:1015-1024
11. Gotfried M,Cassidy J,Marino M, et al.Lung deposition and absorption of insulin from technosphere insulin (abstract 955).Diabetologia. 2009;52:S375
12. Richardson P,Potocka E,Baughman R,Schwartz S,Gray M,Diaz M.Pharmacokinetics of technosphere insulin unchanged in patients with chronic obstructive pulmonary disease (abstract 954).Diabetologia. 2009;52:S375
13. AFREZZA [package insert].Valencia, CA: MannKind Corporation; 2014. http://www.mannkindcorp.com/collateral/documents/english-us/afrezza_prescribinginformation.pdf. Accessed August 25, 2014.
14. Becker RH,Sha S,Frick AD,Fountaine RJ.The effect of smoking cessation and subsequent resumption on absorption of inhaled insulin.Diabetes Care. 2006;29:277-282
15. Baughman R,Cassidy J,Levy B, et al.Technosphere insulin (TI) pharmacokinetics unchanged in subjects who smoke (abstract 427-P).Diabetes. 2008;57:A128
16. Kapsner P,Bergenstal R,Rendell M, et al.Comparative efficacy and safety of technosphere insulin and a rapid-acting analog both given with glargine in subjects with T1 DM in a 52-week study (Poster #982).Diabetologia. 2009;52:
17. MKC-TI-171. Trial 171: a phase 3, multicenter, open-label, randomized, forced-titration clinical trial evaluating the efficacy and safety of Technosphere® insulin inhalation powder in combination with a basal insulin versus insulin aspart in combination with a basal insulin in subjects with type 1 diabetes mellitus over a 24-week treatment period. 2013. Clinical Trials.gov identifier NCT01445951. https://clinicaltrials.gov/ct2/show/NCT01445951?term=NCT01445951&rank=1. Accessed August 25, 2014.
18. MKC-TI-102. Efficacy of meal-time AFRESA in combination with a long-acting basal insulin versus twice daily injections of pre-mixed insulin (a mixture of rapid-acting insulin and intermediate-acting insulin) in patients with type 2 diabetes. 2010. Clinical Trials.gov identifier NCT00309244. https://clinicaltrials.gov/ct2/show/NCT00309244?term=NCT00309244&rank=1. Accessed August 25, 2014.
19. MKC-TI-175. Trial 175: A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized, Clinical Trial Evaluating the Efficacy and Safety of Prandial Technosphere® Insulin Inhalation Powder Versus Technosphere® Inhalation Powder (Placebo) in Insulin Naïve Subjects With Type 2 Diabetes Mellitus Poorly Controlled With Oral Antidiabetic Agents Over a 24-week Treatment Period. 2013. Clinical Trials.gov identifier NCT01451398. https://clinicaltrials.gov/ct2/show/NCT01451398?term=NCT01451398&rank=1. Accessed August 25, 2014.
20. Rosenstock J,Cappelleri JC,Bolinder B,Gerber RA.Patient satisfaction and glycemic control after 1 year with inhaled insulin (Exubera) in patients with type 1 or type 2 diabetes.Diabetes Care. 2004;27:1318-1323
21. Cappelleri JC,Cefalu WT,Rosenstock J,Kourides IA,Gerber RA.Treatment satisfaction in type 2 diabetes: a comparison between an inhaled insulin regimen and a subcutaneous insulin regimen.Clin Ther. 2002;24:552-564
22. McMahon GT,Arky RA.Inhaled insulin for diabetes mellitus.N Engl J Med. 2007;356:497-502
23. Sadri H,MacKeigan LD,Leiter LA,Einarson TR.Willingness to pay for inhaled insulin: a contingent valuation approach.Pharmacoeconomics. 2005;23:1215-1227
24. Petrak F,Herpertz S,Stridde E,Pfutzner A.Psychological insulin resistance in type 2 diabetes patients regarding oral antidiabetes treatment, subcutaneous insulin injections, or inhaled insulin.Diabetes Technol Ther. 2013;15:703-711
25. Peyrot M,Rubin RR.Patient-reported outcomes in adults with type 2 diabetes using mealtime inhaled technosphere insulin and basal insulin versus premixed insulin.Diabetes Technol Ther. 2011;13:1201-1206
26. Rubin RR,Peyrot M.Patient reported outcomes in adults with type 1 diabetes using mealtime AFRESA (inhaled Technosphere insulin) or rapid-acting insulin with basal insulin (abstract 1881-P).Diabetes. 2009;58:A484
27. Wyrwich K,Tierney W,Babu A,Kroenke K,Wolinsky F.A comparison of clinically important differences in health-related quality of life for patients with chronic lung disease, asthma, or heart disease.Health Serv Res. 2005;40:577-592